Valeant Pharmaceuticals: The Hits Keep Coming for VRX Stock
Another Blow for VRX Stock
You may have heard of the heart medication Nitropress before, in what amounted to a rough public relations day for VRX stock: when the company jacked up the price by 525%.
It’s in vogue now for politicians to call out pharmaceutical companies for their price hiking, which may have contributed to the FDA fast-tracking of this generic alternative.
Whatever the reason, VRX stock was predictably hit hard by the news. And if you’ve been following the saga of VRX stock with even detached interest, you’ll know that the last few months have not been kind to the company. Fraud charges toward former executives, investigations, declining share prices; you name it.
Share prices soared as high as $335.00 in mid-2015 before collapsing near the end of the year and continuing that downward spiral throughout 2016. Now VRX stock sits at a comparatively lowly $19.32, or about a 95% decline.
The question is how much more of this can VRX stock take? And, perhaps even more pressing, is there any hope for the shares to regain their once lofty value?
Editor’s Note: Hi, Stephen Karmazyn here. If you enjoyed this article, you can get more of my opinions and commentaries in our popular daily tech letter, Profit Confidential. Published daily, it’s FREE! Join us when you click here now.